A sustainable business model based on innovation and ... - Roche
A sustainable business model based on innovation and ... - Roche
A sustainable business model based on innovation and ... - Roche
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Roche</strong> Pharma pipeline overview<br />
Focused <strong>on</strong> five Disease Biology Areas<br />
Oncology<br />
Xeloda<br />
MabThera<br />
Herceptin<br />
Avastin<br />
Tarceva<br />
Pertuzumab<br />
T-DM1<br />
R7159 3 rd gen anti-CD20<br />
R1507 (IGF-1R mAb)<br />
Apomab<br />
Apo2L/TRAIL<br />
Anti-CD40 mAb<br />
Hedgehog inhibitor<br />
16 ph. I compounds<br />
On H<strong>and</strong><br />
RA/Inflammati<strong>on</strong><br />
MabThera<br />
Actemra<br />
R1594 ocrelizumab<br />
R667 RARγ<br />
9 ph. I compounds<br />
Metabolic/CV<br />
R1658 CETP Inh.<br />
R1583 GLP-1<br />
R1439 dual PPAR<br />
9 ph. I compounds<br />
Promising Late<br />
Stage<br />
Virology<br />
Pegasys<br />
Tamiflu<br />
R3484 HPV16<br />
R7128 HCV pol. Inh.<br />
R7227 HCV prot. inh.<br />
Emerging<br />
Mid-Term<br />
CNS<br />
ocrelizumab RRMS<br />
R1678 Schizophrenia<br />
R3487 Alzheimer’s<br />
4 ph. I compounds<br />
Early<br />
Stage<br />
30
Change language